	Efectivo Y Equivalentes		Fecha
Acadia Pharmaceuticals	USD 847.02M	85.02M	2025-09
Adma Biologics	USD 61.38M	28.9M	2025-09
ALKERMES	USD 616.45M	95.25M	2025-09
Alterity Therapeutics Limited	AUD 15.77M	9.56M	2023-06
AstraZeneca	USD 8.14B	1.08B	2025-09
BioCryst Pharmaceuticals	USD 84.08M	3.95M	2025-09
Bristol-Myers Squibb	USD 10.21B	5.52B	2025-12
Cipla	INR 7.96B	39.9M	2025-09
Clal Biotechnology	ILS 5.73M	1.71M	2023-12
Compugen	USD 7.46M	985K	2025-09
CSL	USD 2.16B	633M	2025-06
Dynavax Technologies	USD 160.25M	61.15M	2025-09
Eli Lilly	USD 9.79B	6.42B	2025-09
Esperion Therapeutics	USD 92.45M	6.39M	2025-09
GlaxoSmithKline	GBP 3.3B	303M	2025-09
Grifols	EUR 979.78M	334.84M	2024-12
Halozyme Therapeutics	USD 419.66M	357.8M	2025-09
Ionis Pharmaceuticals	USD 2.24B	1.94B	2025-09
J&J	USD 18.23B	10.35B	2025-09
Merck	USD 18.17B	10.16B	2025-09
Minerva Neurosciences	USD 12.29M	2.96M	2025-09
Neurocrine Biosciences	USD 340.2M	76.2M	2025-09
Novartis	USD 9.56B	2.9B	2025-09
Novavax	USD 268.02M	14.28M	2025-09
Pfizer	USD 1.34B	295M	2025-09
Roche Holding	CHF 7.55B	579M	2025-06
Sanofi	EUR 7.66B	1.25B	2025-12
Takeda	JPY 654.94B	26.55B	2025-12
Vanda Pharmaceuticals	USD 70.02M	10.96M	2025-09

Minerva Neurosciences Efectivo Y Equivalentes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Feb 2026.